Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


$400m Heptares Acquisition To Drive Sosei’s R&D

This article was originally published in PharmAsia News

Executive Summary

Sosei is to pay up to $400 million to acquire the UK structure-based drug design specialist Heptares Therapeutics in a move that the Japanese firm hopes will bring fresh fuel to its R&D engine, complementing its existing nanotech and peptide technologies.

You may also be interested in...

Takeda To Hunt For New CNS Therapeutics With Heptares' Technology

Takeda Pharmaceutical Company, which has targeted new central nervous system drugs as a core therapeutic research area, entered into a $100 million research collaboration April 11 with the U.K. biotech, Heptares Therapeutics Ltd., to characterize a G-protein coupled receptor (GPCR) believed to play a role in CNS disorders

How To Ensure A Smooth Transition From One EU Notified Body To Another

With notified body capacity becoming increasingly stretched, a new document is available to optimize a transfer, or partial transfer, when this looks to be a manufacturer’s best option for one of a variety of reasons.

Amneal Makes First Biosimilar Launch With US Bevacizumab

Amneal says it has “officially entered the US biosimilar market” after introducing its Alymsys biosimilar bevacizumab rival to Avastin. The biosimilar launch represents the first of three expected for Amneal in 2022, following US FDA approvals earlier this year.


Related Companies

Related Deals

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts